NEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA virus first identified in December 2019 in Wuhan, China, and responsible for coronavirus disease 2019 (COVID-19). The ongoing COVID-19 pandemic is impacting healthcare worldwide. Patients who develop coagulopathy ha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Laure Stiel, Yannick Rabouel, Agathe Debliquis, Valentin Pointurier, Joy Mootien, Khaldoun Kuteifan
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ca84a32caa924e09b4e83e6b644f4645
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ca84a32caa924e09b4e83e6b644f4645
record_format	dspace
spelling	oai:doaj.org-article:ca84a32caa924e09b4e83e6b644f46452021-11-29T00:56:23ZNEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?1875-863010.1155/2021/4361844https://doaj.org/article/ca84a32caa924e09b4e83e6b644f46452021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/4361844https://doaj.org/toc/1875-8630The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA virus first identified in December 2019 in Wuhan, China, and responsible for coronavirus disease 2019 (COVID-19). The ongoing COVID-19 pandemic is impacting healthcare worldwide. Patients who develop coagulopathy have worse outcomes. The pathophysiology of COVID-19 suggests a strong interplay between hemostasis and immune cells, especially neutrophils. Our purpose was to assess neutrophil fluorescence as a potential biomarker of deep vein thrombosis (DVT) in patients with COVID-acute respiratory distress syndrome (COVID-ARDS). Sixty-one patients with COVID-ARDS admitted to the four intensive care units (ICUs) of a French general hospital were included in this prospective study. Neutrophil activation was assessed by measuring neutrophil fluorescence (NEUT-Side Fluorescence Light, NEUT-SFL) with a specific fluorescent dye staining analyzed by a routine automated flow cytometer Sysmex XN-3000™ (Sysmex, Kobe, Japan). DVT was diagnosed by complete duplex ultrasound (CDU). We found that NEUT-SFL was elevated on admission in patients with COVID-ARDS (49.76 AU, reference value 46.40 AU, p<0.001), but did not differ between patients with DVT (49.99 AU) and those without (49.52 AU, p=0.555). NEUT-SFL is elevated in patients with COVID-ARDS, reflecting neutrophil activation, but cannot be used as a marker of thrombosis. Because neutrophils are at interface between immune response and hemostasis through release of neutrophil extracellular traps, monitoring their activation could be an interesting approach to improve our management of coagulopathy during COVID-ARDS. Further research is needed to better understand the pathophysiology of COVID-19 and identify high-performance biomarkers.Laure StielYannick RabouelAgathe DebliquisValentin PointurierJoy MootienKhaldoun KuteifanHindawi LimitedarticleMedicine (General)R5-920ENDisease Markers, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Laure Stiel Yannick Rabouel Agathe Debliquis Valentin Pointurier Joy Mootien Khaldoun Kuteifan NEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?
description	The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA virus first identified in December 2019 in Wuhan, China, and responsible for coronavirus disease 2019 (COVID-19). The ongoing COVID-19 pandemic is impacting healthcare worldwide. Patients who develop coagulopathy have worse outcomes. The pathophysiology of COVID-19 suggests a strong interplay between hemostasis and immune cells, especially neutrophils. Our purpose was to assess neutrophil fluorescence as a potential biomarker of deep vein thrombosis (DVT) in patients with COVID-acute respiratory distress syndrome (COVID-ARDS). Sixty-one patients with COVID-ARDS admitted to the four intensive care units (ICUs) of a French general hospital were included in this prospective study. Neutrophil activation was assessed by measuring neutrophil fluorescence (NEUT-Side Fluorescence Light, NEUT-SFL) with a specific fluorescent dye staining analyzed by a routine automated flow cytometer Sysmex XN-3000™ (Sysmex, Kobe, Japan). DVT was diagnosed by complete duplex ultrasound (CDU). We found that NEUT-SFL was elevated on admission in patients with COVID-ARDS (49.76 AU, reference value 46.40 AU, p<0.001), but did not differ between patients with DVT (49.99 AU) and those without (49.52 AU, p=0.555). NEUT-SFL is elevated in patients with COVID-ARDS, reflecting neutrophil activation, but cannot be used as a marker of thrombosis. Because neutrophils are at interface between immune response and hemostasis through release of neutrophil extracellular traps, monitoring their activation could be an interesting approach to improve our management of coagulopathy during COVID-ARDS. Further research is needed to better understand the pathophysiology of COVID-19 and identify high-performance biomarkers.
format	article
author	Laure Stiel Yannick Rabouel Agathe Debliquis Valentin Pointurier Joy Mootien Khaldoun Kuteifan
author_facet	Laure Stiel Yannick Rabouel Agathe Debliquis Valentin Pointurier Joy Mootien Khaldoun Kuteifan
author_sort	Laure Stiel
title	NEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?
title_short	NEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?
title_full	NEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?
title_fullStr	NEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?
title_full_unstemmed	NEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?
title_sort	neut-sfl in patients with covid-ards: a novel biomarker for thrombotic events?
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/ca84a32caa924e09b4e83e6b644f4645
work_keys_str_mv	AT laurestiel neutsflinpatientswithcovidardsanovelbiomarkerforthromboticevents AT yannickrabouel neutsflinpatientswithcovidardsanovelbiomarkerforthromboticevents AT agathedebliquis neutsflinpatientswithcovidardsanovelbiomarkerforthromboticevents AT valentinpointurier neutsflinpatientswithcovidardsanovelbiomarkerforthromboticevents AT joymootien neutsflinpatientswithcovidardsanovelbiomarkerforthromboticevents AT khaldounkuteifan neutsflinpatientswithcovidardsanovelbiomarkerforthromboticevents
_version_	1718407734465921024

NEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?

Ejemplares similares